feed,title,long_url,short_url
Investors,"Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building",https://www.investors.com/news/technology/dyne-therapeutics-dmd-treatment-executives-step-down/,https://da.gd/lY1ay
